Investigational drug · Phase 3
TQB2450
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Endometrial Cancer, Non Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 27, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
57
Any phase or sponsor naming "TQB2450"
First trial start
2023
Jun 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB2450", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometrial Cancer
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB2450" as an intervention, largest first.
- A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Pivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04234607 · 738 participants (planned) · Start Jan 2020 · Primary completion Dec 2022
Drug: TQB2450; Anlotinib and 4 more · For: Extensive Small Cell Lung Cancer
Sites: Bengbu, China; Hefei, China; Beijing, China · 26 sites in all
- TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Pivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05718167 · 570 participants (planned) · Start Feb 2023 · Primary completion Oct 2024
Drug: TQB2450; Anlotinib hydrochloride capsule and 1 more · For: Advanced Squamous Non-Small Cell Lung Carcinoma
Sites: Beijing, China; Tianjin, China; Kunming, China · 4 sites in all
- A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04523272 · 528 participants · Start Aug 25, 2020 · Primary completion Jun 2025
Drug: TQB2450; Anlotinib and 1 more · For: Advanced Renal Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 39 sites in all
- Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.Pivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05922345 · 518 participants (planned) · Start Jun 8, 2023 · Primary completion Aug 2025
Drug: TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules; TQB2450 placebo, docetaxel injection, AL2846 matching placebo · For: Non-small Cell Lung Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 71 sites in all
- Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial CancerPivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06475599 · 420 participants (planned) · Start Jul 2024 · Primary completion Dec 2027
Drug: Anlotinib hydrochloride capsule + TQB2450 injection; Chemotherapy drug · For: Endometrial Cancer
Sites: Hefei, China; Fuzhou, China; Lanzhou, China · 61 sites in all
- A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian CancerPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05145218 · 405 participants (planned) · Start Sep 28, 2021 · Primary completion Oct 2024
Drug: Anlotinib Hydrochloride Capsules; Paclitaxel injection and 1 more · For: Recurrent Platinum-resistant Ovarian Cancer
Sites: Guangzhou, China; Anyang, China
- A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary CancerPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04809142 · 392 participants (planned) · Start Feb 4, 2021 · Primary completion Mar 18, 2022
Drug: TQB2450 Injection; Anlotinib hydrochloride and 3 more · For: Advanced Biliary Cancer
Sites: Hefei, China; Beijing, China; Fuzhou, China · 17 sites in all
- A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).Pivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05346952 · 390 participants (planned) · Start Jan 25, 2022 · Primary completion Dec 2023
Drug: TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection · For: Advanced Non-squamous Non-small Cell Lung Cancer
Sites: Beijing, China
- A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)Pivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04964479 · 375 participants (planned) · Start Aug 6, 2021 · Primary completion Dec 2022
Drug: TQB2450 injection; Anlotinib Hydrochloride Capsules and 2 more · For: Non Small Cell Lung Cancer
Sites: Beijing, China; Guangzhou, China; Zhangjiang, China · 17 sites in all
- A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06469879 · 358 participants (planned) · Start Sep 2024 · Primary completion Sep 2026
Drug: TQB2450+Anlotinib; TQB2450 placebo + Anlotinib placebo · For: Small Cell Lung Cancer Limited Stage
Sites: Hefei, China; Lanzhou, China; Nanjing, China · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- TLR7 agonist plus anti-PD-L1 enhances HBsAg decline and reinvigorates HBV-specific CD8+ T cells: OCEANcure05 RCT study.
Chen Y, Wu T, Huang D, et al. · Clin Mol Hepatol 2026
- Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors in malignant solid tumors: a meta-analysis and network meta-analysis.
Wang C, Wang N, Wu Z, et al. · Front Immunol 2026
- Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs.
Gong C, Huang J, Cao D, et al. · Ther Adv Med Oncol 2025
- Surgery after induced anti-PD-L1 therapy and chemotherapy for stage IߜIII small-cell lung cancer: a phase 2 trial (LungMate-005).
Sun F, Zhang L, Sun L, et al. · Cell Discov 2025
- TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial.
Xia TL, Huang W, Liu YP, et al. · Med 2025
- Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study.
Yuan H, Li Y, Zhao K, et al. · Front Immunol 2025
Also in development for Endometrial Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- Rina-SPRO1184, GEN1184Phase 39 trials
Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials
AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.